

# Global Gene Editing Safety Analysis Software Market 2026 by Company, Regions, Type and Application, Forecast to 2032

<https://marketpublishers.com/r/GD9A022933B6EN.html>

Date: September 2026

Pages: 105

Price: US\$ 3,480.00 (Single User License)

ID: GD9A022933B6EN

## Abstracts

According to our (Global Info Research) latest study, the global Gene Editing Safety Analysis Software market size was valued at US\$ 243 million in 2025 and is forecast to a readjusted size of US\$ 649 million by 2032 with a CAGR of 15.0% during review period.

Gene editing safety analysis software comprises bioinformatics applications and digital analytics platforms used to identify, quantify, and manage safety risks associated with genome editing. The category covers pre-edit guide RNA specificity assessment and potential off-target prediction, as well as post-edit interpretation of Sanger, targeted NGS, whole-genome, and long-read sequencing data. Products are delivered as cloud SaaS, public web tools, desktop applications, on-premises or private-cloud systems, and modules within enterprise R&D platforms. Core functions include editing-efficiency and allele-profile quantification, candidate off-target nomination and confirmation, low-frequency variant detection, identification of large deletions and chromosomal rearrangements, cross-sample comparison, audit trails, and compliance-oriented reporting. This study focuses on products commercialized through software licenses, subscriptions, cloud-analysis fees, or software bundled with reagents and analytical services for biopharmaceutical, cell and gene therapy, contract research, academic, agricultural biotechnology, and testing-laboratory users. The blended gross margin is approximately 75%.

## Market Trends

Gene editing safety analysis is shifting from isolated guide-RNA scoring or edit-

efficiency calculations toward integrated workflows that connect edit design, candidate off-target nomination, experimental confirmation, structural-variant identification, and regulatory documentation. As base editing, prime editing, and emerging nucleases enter more development programs, software must evaluate non-double-strand-break edits, editing-window bias, bystander edits, large deletions, and complex rearrangements. Product development is moving beyond single-algorithm accuracy toward orthogonal model comparison, population-variant awareness, long-read compatibility, automated quality control, explainable outputs, and standardized reports, with growing integration into electronic laboratory notebooks, sample-management systems, sequencing platforms, and enterprise data environments.

## **Drivers**

Growth in cell and gene therapy programs, stronger regulatory expectations for off-target and genome-integrity evidence, and pressure to shorten guide-selection and sequencing-interpretation cycles are supporting demand for specialized software. High-throughput experiments generate rapidly increasing sample volumes, candidate loci, and data types, while general-purpose scripts and disconnected tools make version control, parameter consistency, and result traceability difficult. This is encouraging companies to adopt validated commercial platforms or controlled deployment models.

## **Restraints**

Many foundational prediction and outcome-analysis tools are available free of charge or as open-source software, limiting direct willingness to pay in academic research. The absence of harmonized benchmarks across editors, cell types, and assay methods makes performance difficult to compare through a single metric. High-quality training sets, verified positive off-target events, and validated structural-variant datasets also remain constrained, increasing software-validation and customer-onboarding costs.

## **Opportunities**

Compliance-oriented analysis for preclinical and regulatory programs, population-genome-aware prediction, integration of long-read and single-cell data, and dedicated risk models for base and prime editing represent the most attractive expansion areas. Platforms that support private deployment, configurable pipelines, audit trails, and standardized validation documentation can move from project-level tools to enterprise

safety-analysis infrastructure. Integration with sequencing reagents, off-target testing services, and automated laboratory platforms can also create recurring revenue streams.

## Challenges

Computational prediction cannot replace experimental confirmation, and overstating the clinical meaning of predicted sites may create development and compliance risk. Rapid editing-technology evolution requires continuous maintenance of reference genomes, PAM rules, scoring models, and variant databases. Customer datasets may contain confidential targets, patient-derived information, and valuable intellectual property, making cross-border data handling, cloud security, and permission management increasingly complex. Limited concordance among experimental methods may also prevent software outputs from being directly comparable across programs.

## Value Chain Analysis

Upstream value is created by reference genomes and variant databases, editor-activity and off-target training datasets, sequencing algorithms, cloud-computing resources, and security and compliance infrastructure. Midstream suppliers convert these inputs into guide-design, edit-outcome interpretation, off-target nomination, structural-variant analysis, and reporting modules, differentiating through algorithm validation, user experience, workflow orchestration, and technical support. Downstream users prioritize speed and accessibility during discovery, while preclinical and regulatory teams place greater weight on detection capability, locked parameters, audit records, data isolation, and method-transfer support. Software has low marginal delivery cost, but expert bioinformatics staff, continuous validation, customer configuration, and compliance support remain major cost components. Suppliers that convert one-time analysis into enterprise subscriptions or platform standards can achieve stronger retention.

## Segment Insights

By primary function, guide design and off-target prediction have the broadest user base, but extensive free-tool availability means commercial value is concentrated in enterprise collaboration, batch design, proprietary genomes, and data governance. Editing-outcome quantification maintains frequent research use: Sanger-based tools emphasize low cost and rapid feedback, whereas targeted-NGS software is better suited to low-

frequency event quantification and multi-locus confirmation. The higher-growth opportunities are genome-wide off-target discovery, genome-integrity and structural-variant analysis, and integrated safety platforms that combine multiple assay outputs into an auditable evidence chain, because these functions are more closely aligned with clinical-development and regulatory-support budgets.

## **Downstream Market Opportunities**

Biopharmaceutical and cell and gene therapy companies are the highest-value customers, with purchasing needs extending from early editor screening to candidate confirmation, process-change comparability, and regulatory support. Contract research and testing organizations require reusable and validated pipelines for multiple clients and therefore prioritize batch processing, project separation, and standardized reporting. Academic and government institutes remain important for tool adoption and method innovation but are more price sensitive. Agricultural and industrial biotechnology users place greater emphasis on multi-species genome support, high-volume guide design, and cost-controlled local deployment.

## **Regional Insights**

North America remains the largest regional market because gene editing therapeutic pipelines, specialized bioinformatics talent, sequencing infrastructure, and enterprise software budgets are concentrated there. Europe's rigorous quality and nonclinical evidence expectations for advanced therapies support demand for controlled analysis and documented workflows, although data-governance requirements and procurement cycles can be longer. Asia-Pacific has strong expansion potential as cell therapy, gene therapy, synthetic biology, and domestic sequencing ecosystems develop across China, Japan, South Korea, and Singapore. Customers in the region show greater preference for local technical support, private deployment, and compatibility with regional databases. Other regions remain more dependent on research institutions and centralized sequencing facilities, where cloud tools can reduce initial deployment barriers.

## **Competitive Landscape Analysis**

Competition includes life-science R&D platform providers, sequence-analysis software

companies, gene editing reagent suppliers, and specialist safety-analytics firms, creating a fragmented market with diverse commercial models. Integrated platforms enter large enterprise accounts through laboratory records, collaboration, and data governance; specialized software vendors compete through algorithm depth, sequence visualization, and desktop deployment; and reagent or testing-service suppliers use free or bundled software to support consumable and project revenue. Competitive advantage depends not only on the number of algorithms but also on validation evidence, editor coverage, difficult-region performance, structural-variant capability, explainability, audit trails, deployment security, and support quality. Future consolidation is more likely to combine software with testing services, sequencing workflows, or enterprise R&D platforms, while free tools will continue to constrain pricing for basic functions.

## Report Scope

This report is a detailed and comprehensive analysis for global Gene Editing Safety Analysis Software market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

## Key Features:

Global Gene Editing Safety Analysis Software market size and forecasts, in consumption value (\$ Million), 2021-2032

Global Gene Editing Safety Analysis Software market size and forecasts by region and country, in consumption value (\$ Million), 2021-2032

Global Gene Editing Safety Analysis Software market size and forecasts, by Type and by Application, in consumption value (\$ Million), 2021-2032

Global Gene Editing Safety Analysis Software market shares of main players, in revenue (\$ Million), 2021-2026

## The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Gene Editing Safety Analysis Software

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Gene Editing Safety Analysis Software market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Benchling, Dotmatics, EditCo, Integrated DNA Technologies, Thermo Fisher Scientific, GenScript, Agilent Technologies, Merck, VectorBuilder, MaxCyte, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Gene Editing Safety Analysis Software market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

## Market segmentation

### Market segment by Type

Standalone Subscription or License

Reagent-Bundled Analysis Software

Service-Bundled Analysis Software

Free or Open-Source Tools

## **Market segment by Deployment Model**

Public Web Tools

Commercial Cloud SaaS

Desktop Applications

On-Premises or Private-Cloud Software

Hybrid Deployment

## **Market segment by Primary Input Data**

Sequence and Genome Annotation Data

Sanger Sequencing Data

Targeted Amplicon NGS Data

Genome-Wide NGS Data

Long-Read Sequencing Data

Multi-Assay Data

## **Market segment by Application**

Biopharmaceutical and Cell & Gene Therapy Companies

Clinical and Independent Testing Laboratories

Academic and Government Research Institutes

Agricultural Biotechnology Companies

Industrial Biotechnology Companies

## **Market segment by players, this report covers**

Benchling

Dotmatics

EditCo

Integrated DNA Technologies

Thermo Fisher Scientific

GenScript

Agilent Technologies

Merck

VectorBuilder

MaxCyte

CRISPR QC

Revvity

## **Market segment by regions, regional analysis covers**

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

## Chapter Outline

Chapter 1, to describe Gene Editing Safety Analysis Software product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Gene Editing Safety Analysis Software, with revenue, gross margin, and global market share of Gene Editing Safety Analysis Software from 2021 to 2026.

Chapter 3, the Gene Editing Safety Analysis Software competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026. and Gene Editing Safety Analysis Software market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Gene Editing Safety Analysis Software.

Chapter 13, to describe Gene Editing Safety Analysis Software research findings and conclusion.

## Contents

### 1 MARKET OVERVIEW

#### 1.1 Product Overview and Scope

#### 1.2 Market Estimation Caveats and Base Year

#### 1.3 Classification of Gene Editing Safety Analysis Software by Type

##### 1.3.1 Overview: Global Gene Editing Safety Analysis Software Market Size by Type: 2021 Versus 2025 Versus 2032

##### 1.3.2 Global Gene Editing Safety Analysis Software Consumption Value Market Share by Type in 2025

##### 1.3.3 Standalone Subscription or License

##### 1.3.4 Reagent-Bundled Analysis Software

##### 1.3.5 Service-Bundled Analysis Software

##### 1.3.6 Free or Open-Source Tools

#### 1.4 Classification of Gene Editing Safety Analysis Software by Deployment Model

##### 1.4.1 Overview: Global Gene Editing Safety Analysis Software Market Size by Deployment Model: 2021 Versus 2025 Versus 2032

##### 1.4.2 Global Gene Editing Safety Analysis Software Consumption Value Market Share by Deployment Model in 2025

##### 1.4.3 Public Web Tools

##### 1.4.4 Commercial Cloud SaaS

##### 1.4.5 Desktop Applications

##### 1.4.6 On-Premises or Private-Cloud Software

##### 1.4.7 Hybrid Deployment

#### 1.5 Classification of Gene Editing Safety Analysis Software by Primary Input Data

##### 1.5.1 Overview: Global Gene Editing Safety Analysis Software Market Size by Primary Input Data: 2021 Versus 2025 Versus 2032

##### 1.5.2 Global Gene Editing Safety Analysis Software Consumption Value Market Share by Primary Input Data in 2025

##### 1.5.3 Sequence and Genome Annotation Data

##### 1.5.4 Sanger Sequencing Data

##### 1.5.5 Targeted Amplicon NGS Data

##### 1.5.6 Genome-Wide NGS Data

##### 1.5.7 Long-Read Sequencing Data

##### 1.5.8 Multi-Assay Data

#### 1.6 Global Gene Editing Safety Analysis Software Market by Application

##### 1.6.1 Overview: Global Gene Editing Safety Analysis Software Market Size by Application: 2021 Versus 2025 Versus 2032

- 1.6.2 Biopharmaceutical and Cell & Gene Therapy Companies
- 1.6.3 Clinical and Independent Testing Laboratories
- 1.6.4 Academic and Government Research Institutes
- 1.6.5 Agricultural Biotechnology Companies
- 1.6.6 Industrial Biotechnology Companies
- 1.7 Global Gene Editing Safety Analysis Software Market Size & Forecast
- 1.8 Global Gene Editing Safety Analysis Software Market Size and Forecast by Region
  - 1.8.1 Global Gene Editing Safety Analysis Software Market Size by Region: 2021 VS 2025 VS 2032
  - 1.8.2 Global Gene Editing Safety Analysis Software Market Size by Region, (2021-2032)
  - 1.8.3 North America Gene Editing Safety Analysis Software Market Size and Prospect (2021-2032)
  - 1.8.4 Europe Gene Editing Safety Analysis Software Market Size and Prospect (2021-2032)
  - 1.8.5 Asia-Pacific Gene Editing Safety Analysis Software Market Size and Prospect (2021-2032)
  - 1.8.6 South America Gene Editing Safety Analysis Software Market Size and Prospect (2021-2032)
  - 1.8.7 Middle East & Africa Gene Editing Safety Analysis Software Market Size and Prospect (2021-2032)

## **2 COMPANY PROFILES**

- 2.1 Benchling
  - 2.1.1 Benchling Details
  - 2.1.2 Benchling Major Business
  - 2.1.3 Benchling Gene Editing Safety Analysis Software Product and Solutions
  - 2.1.4 Benchling Gene Editing Safety Analysis Software Revenue, Gross Margin and Market Share (2021-2026)
  - 2.1.5 Benchling Recent Developments and Future Plans
- 2.2 Dotmatics
  - 2.2.1 Dotmatics Details
  - 2.2.2 Dotmatics Major Business
  - 2.2.3 Dotmatics Gene Editing Safety Analysis Software Product and Solutions
  - 2.2.4 Dotmatics Gene Editing Safety Analysis Software Revenue, Gross Margin and Market Share (2021-2026)
  - 2.2.5 Dotmatics Recent Developments and Future Plans
- 2.3 EditCo

- 2.3.1 EditCo Details
- 2.3.2 EditCo Major Business
- 2.3.3 EditCo Gene Editing Safety Analysis Software Product and Solutions
- 2.3.4 EditCo Gene Editing Safety Analysis Software Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 EditCo Recent Developments and Future Plans
- 2.4 Integrated DNA Technologies
  - 2.4.1 Integrated DNA Technologies Details
  - 2.4.2 Integrated DNA Technologies Major Business
  - 2.4.3 Integrated DNA Technologies Gene Editing Safety Analysis Software Product and Solutions
  - 2.4.4 Integrated DNA Technologies Gene Editing Safety Analysis Software Revenue, Gross Margin and Market Share (2021-2026)
  - 2.4.5 Integrated DNA Technologies Recent Developments and Future Plans
- 2.5 Thermo Fisher Scientific
  - 2.5.1 Thermo Fisher Scientific Details
  - 2.5.2 Thermo Fisher Scientific Major Business
  - 2.5.3 Thermo Fisher Scientific Gene Editing Safety Analysis Software Product and Solutions
  - 2.5.4 Thermo Fisher Scientific Gene Editing Safety Analysis Software Revenue, Gross Margin and Market Share (2021-2026)
  - 2.5.5 Thermo Fisher Scientific Recent Developments and Future Plans
- 2.6 GenScript
  - 2.6.1 GenScript Details
  - 2.6.2 GenScript Major Business
  - 2.6.3 GenScript Gene Editing Safety Analysis Software Product and Solutions
  - 2.6.4 GenScript Gene Editing Safety Analysis Software Revenue, Gross Margin and Market Share (2021-2026)
  - 2.6.5 GenScript Recent Developments and Future Plans
- 2.7 Agilent Technologies
  - 2.7.1 Agilent Technologies Details
  - 2.7.2 Agilent Technologies Major Business
  - 2.7.3 Agilent Technologies Gene Editing Safety Analysis Software Product and Solutions
  - 2.7.4 Agilent Technologies Gene Editing Safety Analysis Software Revenue, Gross Margin and Market Share (2021-2026)
  - 2.7.5 Agilent Technologies Recent Developments and Future Plans
- 2.8 Merck
  - 2.8.1 Merck Details

- 2.8.2 Merck Major Business
- 2.8.3 Merck Gene Editing Safety Analysis Software Product and Solutions
- 2.8.4 Merck Gene Editing Safety Analysis Software Revenue, Gross Margin and Market Share (2021-2026)
- 2.8.5 Merck Recent Developments and Future Plans
- 2.9 VectorBuilder
  - 2.9.1 VectorBuilder Details
  - 2.9.2 VectorBuilder Major Business
  - 2.9.3 VectorBuilder Gene Editing Safety Analysis Software Product and Solutions
  - 2.9.4 VectorBuilder Gene Editing Safety Analysis Software Revenue, Gross Margin and Market Share (2021-2026)
  - 2.9.5 VectorBuilder Recent Developments and Future Plans
- 2.10 MaxCyte
  - 2.10.1 MaxCyte Details
  - 2.10.2 MaxCyte Major Business
  - 2.10.3 MaxCyte Gene Editing Safety Analysis Software Product and Solutions
  - 2.10.4 MaxCyte Gene Editing Safety Analysis Software Revenue, Gross Margin and Market Share (2021-2026)
  - 2.10.5 MaxCyte Recent Developments and Future Plans
- 2.11 CRISPR QC
  - 2.11.1 CRISPR QC Details
  - 2.11.2 CRISPR QC Major Business
  - 2.11.3 CRISPR QC Gene Editing Safety Analysis Software Product and Solutions
  - 2.11.4 CRISPR QC Gene Editing Safety Analysis Software Revenue, Gross Margin and Market Share (2021-2026)
  - 2.11.5 CRISPR QC Recent Developments and Future Plans
- 2.12 Revvity
  - 2.12.1 Revvity Details
  - 2.12.2 Revvity Major Business
  - 2.12.3 Revvity Gene Editing Safety Analysis Software Product and Solutions
  - 2.12.4 Revvity Gene Editing Safety Analysis Software Revenue, Gross Margin and Market Share (2021-2026)
  - 2.12.5 Revvity Recent Developments and Future Plans

### **3 MARKET COMPETITION, BY PLAYERS**

- 3.1 Global Gene Editing Safety Analysis Software Revenue and Share by Players (2021-2026)
- 3.2 Market Share Analysis (2025)

- 3.2.1 Market Share of Gene Editing Safety Analysis Software by Company Revenue
- 3.2.2 Top 3 Gene Editing Safety Analysis Software Players Market Share in 2025
- 3.2.3 Top 6 Gene Editing Safety Analysis Software Players Market Share in 2025
- 3.3 Gene Editing Safety Analysis Software Market: Overall Company Footprint Analysis
  - 3.3.1 Gene Editing Safety Analysis Software Market: Region Footprint
  - 3.3.2 Gene Editing Safety Analysis Software Market: Company Product Type Footprint
  - 3.3.3 Gene Editing Safety Analysis Software Market: Company Product Application Footprint
- 3.4 New Market Entrants and Barriers to Market Entry
- 3.5 Mergers, Acquisition, Agreements, and Collaborations

## **4 MARKET SIZE SEGMENT BY TYPE**

- 4.1 Global Gene Editing Safety Analysis Software Consumption Value and Market Share by Type (2021-2026)
- 4.2 Global Gene Editing Safety Analysis Software Market Forecast by Type (2027-2032)

## **5 MARKET SIZE SEGMENT BY APPLICATION**

- 5.1 Global Gene Editing Safety Analysis Software Consumption Value Market Share by Application (2021-2026)
- 5.2 Global Gene Editing Safety Analysis Software Market Forecast by Application (2027-2032)

## **6 NORTH AMERICA**

- 6.1 North America Gene Editing Safety Analysis Software Consumption Value by Type (2021-2032)
- 6.2 North America Gene Editing Safety Analysis Software Market Size by Application (2021-2032)
- 6.3 North America Gene Editing Safety Analysis Software Market Size by Country
  - 6.3.1 North America Gene Editing Safety Analysis Software Consumption Value by Country (2021-2032)
  - 6.3.2 United States Gene Editing Safety Analysis Software Market Size and Forecast (2021-2032)
  - 6.3.3 Canada Gene Editing Safety Analysis Software Market Size and Forecast (2021-2032)
  - 6.3.4 Mexico Gene Editing Safety Analysis Software Market Size and Forecast

(2021-2032)

## **7 EUROPE**

7.1 Europe Gene Editing Safety Analysis Software Consumption Value by Type  
(2021-2032)

7.2 Europe Gene Editing Safety Analysis Software Consumption Value by Application  
(2021-2032)

7.3 Europe Gene Editing Safety Analysis Software Market Size by Country

7.3.1 Europe Gene Editing Safety Analysis Software Consumption Value by Country  
(2021-2032)

7.3.2 Germany Gene Editing Safety Analysis Software Market Size and Forecast  
(2021-2032)

7.3.3 France Gene Editing Safety Analysis Software Market Size and Forecast  
(2021-2032)

7.3.4 United Kingdom Gene Editing Safety Analysis Software Market Size and  
Forecast (2021-2032)

7.3.5 Russia Gene Editing Safety Analysis Software Market Size and Forecast  
(2021-2032)

7.3.6 Italy Gene Editing Safety Analysis Software Market Size and Forecast  
(2021-2032)

## **8 ASIA-PACIFIC**

8.1 Asia-Pacific Gene Editing Safety Analysis Software Consumption Value by Type  
(2021-2032)

8.2 Asia-Pacific Gene Editing Safety Analysis Software Consumption Value by  
Application (2021-2032)

8.3 Asia-Pacific Gene Editing Safety Analysis Software Market Size by Region

8.3.1 Asia-Pacific Gene Editing Safety Analysis Software Consumption Value by  
Region (2021-2032)

8.3.2 China Gene Editing Safety Analysis Software Market Size and Forecast  
(2021-2032)

8.3.3 Japan Gene Editing Safety Analysis Software Market Size and Forecast  
(2021-2032)

8.3.4 South Korea Gene Editing Safety Analysis Software Market Size and Forecast  
(2021-2032)

8.3.5 India Gene Editing Safety Analysis Software Market Size and Forecast  
(2021-2032)

8.3.6 Southeast Asia Gene Editing Safety Analysis Software Market Size and Forecast (2021-2032)

8.3.7 Australia Gene Editing Safety Analysis Software Market Size and Forecast (2021-2032)

## **9 SOUTH AMERICA**

9.1 South America Gene Editing Safety Analysis Software Consumption Value by Type (2021-2032)

9.2 South America Gene Editing Safety Analysis Software Consumption Value by Application (2021-2032)

9.3 South America Gene Editing Safety Analysis Software Market Size by Country

9.3.1 South America Gene Editing Safety Analysis Software Consumption Value by Country (2021-2032)

9.3.2 Brazil Gene Editing Safety Analysis Software Market Size and Forecast (2021-2032)

9.3.3 Argentina Gene Editing Safety Analysis Software Market Size and Forecast (2021-2032)

## **10 MIDDLE EAST & AFRICA**

10.1 Middle East & Africa Gene Editing Safety Analysis Software Consumption Value by Type (2021-2032)

10.2 Middle East & Africa Gene Editing Safety Analysis Software Consumption Value by Application (2021-2032)

10.3 Middle East & Africa Gene Editing Safety Analysis Software Market Size by Country

10.3.1 Middle East & Africa Gene Editing Safety Analysis Software Consumption Value by Country (2021-2032)

10.3.2 Turkey Gene Editing Safety Analysis Software Market Size and Forecast (2021-2032)

10.3.3 Saudi Arabia Gene Editing Safety Analysis Software Market Size and Forecast (2021-2032)

10.3.4 UAE Gene Editing Safety Analysis Software Market Size and Forecast (2021-2032)

## **11 MARKET DYNAMICS**

11.1 Gene Editing Safety Analysis Software Market Drivers

11.2 Gene Editing Safety Analysis Software Market Restraints

11.3 Gene Editing Safety Analysis Software Trends Analysis

11.4 Porters Five Forces Analysis

11.4.1 Threat of New Entrants

11.4.2 Bargaining Power of Suppliers

11.4.3 Bargaining Power of Buyers

11.4.4 Threat of Substitutes

11.4.5 Competitive Rivalry

## **12 INDUSTRY CHAIN ANALYSIS**

12.1 Gene Editing Safety Analysis Software Industry Chain

12.2 Gene Editing Safety Analysis Software Upstream Analysis

12.3 Gene Editing Safety Analysis Software Midstream Analysis

12.4 Gene Editing Safety Analysis Software Downstream Analysis

## **13 RESEARCH FINDINGS AND CONCLUSION**

## **14 APPENDIX**

14.1 Methodology

14.2 Research Process and Data Source

14.3 Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1. Global Gene Editing Safety Analysis Software Consumption Value by Type, (USD Million), 2021 & 2025 & 2032

Table 2. Global Gene Editing Safety Analysis Software Consumption Value by Deployment Model, (USD Million), 2021 & 2025 & 2032

Table 3. Global Gene Editing Safety Analysis Software Consumption Value by Primary Input Data, (USD Million), 2021 & 2025 & 2032

Table 4. Global Gene Editing Safety Analysis Software Consumption Value by Application, (USD Million), 2021 & 2025 & 2032

Table 5. Global Gene Editing Safety Analysis Software Consumption Value by Region (2021-2026) & (USD Million)

Table 6. Global Gene Editing Safety Analysis Software Consumption Value by Region (2027-2032) & (USD Million)

Table 7. Benchling Company Information, Head Office, and Major Competitors

Table 8. Benchling Major Business

Table 9. Benchling Gene Editing Safety Analysis Software Product and Solutions

Table 10. Benchling Gene Editing Safety Analysis Software Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 11. Benchling Recent Developments and Future Plans

Table 12. Dotmatics Company Information, Head Office, and Major Competitors

Table 13. Dotmatics Major Business

Table 14. Dotmatics Gene Editing Safety Analysis Software Product and Solutions

Table 15. Dotmatics Gene Editing Safety Analysis Software Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 16. Dotmatics Recent Developments and Future Plans

Table 17. EditCo Company Information, Head Office, and Major Competitors

Table 18. EditCo Major Business

Table 19. EditCo Gene Editing Safety Analysis Software Product and Solutions

Table 20. EditCo Gene Editing Safety Analysis Software Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 21. Integrated DNA Technologies Company Information, Head Office, and Major Competitors

Table 22. Integrated DNA Technologies Major Business

Table 23. Integrated DNA Technologies Gene Editing Safety Analysis Software Product and Solutions

Table 24. Integrated DNA Technologies Gene Editing Safety Analysis Software

Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 25. Integrated DNA Technologies Recent Developments and Future Plans

Table 26. Thermo Fisher Scientific Company Information, Head Office, and Major Competitors

Table 27. Thermo Fisher Scientific Major Business

Table 28. Thermo Fisher Scientific Gene Editing Safety Analysis Software Product and Solutions

Table 29. Thermo Fisher Scientific Gene Editing Safety Analysis Software Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 30. Thermo Fisher Scientific Recent Developments and Future Plans

Table 31. GenScript Company Information, Head Office, and Major Competitors

Table 32. GenScript Major Business

Table 33. GenScript Gene Editing Safety Analysis Software Product and Solutions

Table 34. GenScript Gene Editing Safety Analysis Software Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 35. GenScript Recent Developments and Future Plans

Table 36. Agilent Technologies Company Information, Head Office, and Major Competitors

Table 37. Agilent Technologies Major Business

Table 38. Agilent Technologies Gene Editing Safety Analysis Software Product and Solutions

Table 39. Agilent Technologies Gene Editing Safety Analysis Software Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 40. Agilent Technologies Recent Developments and Future Plans

Table 41. Merck Company Information, Head Office, and Major Competitors

Table 42. Merck Major Business

Table 43. Merck Gene Editing Safety Analysis Software Product and Solutions

Table 44. Merck Gene Editing Safety Analysis Software Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 45. Merck Recent Developments and Future Plans

Table 46. VectorBuilder Company Information, Head Office, and Major Competitors

Table 47. VectorBuilder Major Business

Table 48. VectorBuilder Gene Editing Safety Analysis Software Product and Solutions

Table 49. VectorBuilder Gene Editing Safety Analysis Software Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 50. VectorBuilder Recent Developments and Future Plans

Table 51. MaxCyte Company Information, Head Office, and Major Competitors

Table 52. MaxCyte Major Business

Table 53. MaxCyte Gene Editing Safety Analysis Software Product and Solutions

Table 54. MaxCyte Gene Editing Safety Analysis Software Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 55. MaxCyte Recent Developments and Future Plans

Table 56. CRISPR QC Company Information, Head Office, and Major Competitors

Table 57. CRISPR QC Major Business

Table 58. CRISPR QC Gene Editing Safety Analysis Software Product and Solutions

Table 59. CRISPR QC Gene Editing Safety Analysis Software Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 60. CRISPR QC Recent Developments and Future Plans

Table 61. Revvity Company Information, Head Office, and Major Competitors

Table 62. Revvity Major Business

Table 63. Revvity Gene Editing Safety Analysis Software Product and Solutions

Table 64. Revvity Gene Editing Safety Analysis Software Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 65. Revvity Recent Developments and Future Plans

Table 66. Global Gene Editing Safety Analysis Software Revenue (USD Million) by Players (2021-2026)

Table 67. Global Gene Editing Safety Analysis Software Revenue Share by Players (2021-2026)

Table 68. Breakdown of Gene Editing Safety Analysis Software by Company Type (Tier 1, Tier 2, and Tier 3)

Table 69. Market Position of Players in Gene Editing Safety Analysis Software, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025

Table 70. Head Office of Key Gene Editing Safety Analysis Software Players

Table 71. Gene Editing Safety Analysis Software Market: Company Product Type Footprint

Table 72. Gene Editing Safety Analysis Software Market: Company Product Application Footprint

Table 73. Gene Editing Safety Analysis Software New Market Entrants and Barriers to Market Entry

Table 74. Gene Editing Safety Analysis Software Mergers, Acquisition, Agreements, and Collaborations

Table 75. Global Gene Editing Safety Analysis Software Consumption Value (USD Million) by Type (2021-2026)

Table 76. Global Gene Editing Safety Analysis Software Consumption Value Share by Type (2021-2026)

Table 77. Global Gene Editing Safety Analysis Software Consumption Value Forecast by Type (2027-2032)

Table 78. Global Gene Editing Safety Analysis Software Consumption Value by

Application (2021-2026)

Table 79. Global Gene Editing Safety Analysis Software Consumption Value Forecast by Application (2027-2032)

Table 80. North America Gene Editing Safety Analysis Software Consumption Value by Type (2021-2026) & (USD Million)

Table 81. North America Gene Editing Safety Analysis Software Consumption Value by Type (2027-2032) & (USD Million)

Table 82. North America Gene Editing Safety Analysis Software Consumption Value by Application (2021-2026) & (USD Million)

Table 83. North America Gene Editing Safety Analysis Software Consumption Value by Application (2027-2032) & (USD Million)

Table 84. North America Gene Editing Safety Analysis Software Consumption Value by Country (2021-2026) & (USD Million)

Table 85. North America Gene Editing Safety Analysis Software Consumption Value by Country (2027-2032) & (USD Million)

Table 86. Europe Gene Editing Safety Analysis Software Consumption Value by Type (2021-2026) & (USD Million)

Table 87. Europe Gene Editing Safety Analysis Software Consumption Value by Type (2027-2032) & (USD Million)

Table 88. Europe Gene Editing Safety Analysis Software Consumption Value by Application (2021-2026) & (USD Million)

Table 89. Europe Gene Editing Safety Analysis Software Consumption Value by Application (2027-2032) & (USD Million)

Table 90. Europe Gene Editing Safety Analysis Software Consumption Value by Country (2021-2026) & (USD Million)

Table 91. Europe Gene Editing Safety Analysis Software Consumption Value by Country (2027-2032) & (USD Million)

Table 92. Asia-Pacific Gene Editing Safety Analysis Software Consumption Value by Type (2021-2026) & (USD Million)

Table 93. Asia-Pacific Gene Editing Safety Analysis Software Consumption Value by Type (2027-2032) & (USD Million)

Table 94. Asia-Pacific Gene Editing Safety Analysis Software Consumption Value by Application (2021-2026) & (USD Million)

Table 95. Asia-Pacific Gene Editing Safety Analysis Software Consumption Value by Application (2027-2032) & (USD Million)

Table 96. Asia-Pacific Gene Editing Safety Analysis Software Consumption Value by Region (2021-2026) & (USD Million)

Table 97. Asia-Pacific Gene Editing Safety Analysis Software Consumption Value by Region (2027-2032) & (USD Million)

Table 98. South America Gene Editing Safety Analysis Software Consumption Value by Type (2021-2026) & (USD Million)

Table 99. South America Gene Editing Safety Analysis Software Consumption Value by Type (2027-2032) & (USD Million)

Table 100. South America Gene Editing Safety Analysis Software Consumption Value by Application (2021-2026) & (USD Million)

Table 101. South America Gene Editing Safety Analysis Software Consumption Value by Application (2027-2032) & (USD Million)

Table 102. South America Gene Editing Safety Analysis Software Consumption Value by Country (2021-2026) & (USD Million)

Table 103. South America Gene Editing Safety Analysis Software Consumption Value by Country (2027-2032) & (USD Million)

Table 104. Middle East & Africa Gene Editing Safety Analysis Software Consumption Value by Type (2021-2026) & (USD Million)

Table 105. Middle East & Africa Gene Editing Safety Analysis Software Consumption Value by Type (2027-2032) & (USD Million)

Table 106. Middle East & Africa Gene Editing Safety Analysis Software Consumption Value by Application (2021-2026) & (USD Million)

Table 107. Middle East & Africa Gene Editing Safety Analysis Software Consumption Value by Application (2027-2032) & (USD Million)

Table 108. Middle East & Africa Gene Editing Safety Analysis Software Consumption Value by Country (2021-2026) & (USD Million)

Table 109. Middle East & Africa Gene Editing Safety Analysis Software Consumption Value by Country (2027-2032) & (USD Million)

Table 110. Global Key Players of Gene Editing Safety Analysis Software Upstream (Raw Materials)

Table 111. Global Gene Editing Safety Analysis Software Typical Customers

## List Of Figures

### LIST OF FIGURES

Figure 1. Gene Editing Safety Analysis Software Picture

Figure 2. Global Gene Editing Safety Analysis Software Consumption Value by Type, (USD Million), 2021 & 2025 & 2032

Figure 3. Global Gene Editing Safety Analysis Software Consumption Value Market Share by Type in 2025

Figure 4. Standalone Subscription or License

Figure 5. Reagent-Bundled Analysis Software

Figure 6. Service-Bundled Analysis Software

Figure 7. Free or Open-Source Tools

Figure 8. Global Gene Editing Safety Analysis Software Consumption Value by Deployment Model, (USD Million), 2021 & 2025 & 2032

Figure 9. Global Gene Editing Safety Analysis Software Consumption Value Market Share by Deployment Model in 2025

Figure 10. Public Web Tools

Figure 11. Commercial Cloud SaaS

Figure 12. Desktop Applications

Figure 13. On-Premises or Private-Cloud Software

Figure 14. Hybrid Deployment

Figure 15. Global Gene Editing Safety Analysis Software Consumption Value by Primary Input Data, (USD Million), 2021 & 2025 & 2032

Figure 16. Global Gene Editing Safety Analysis Software Consumption Value Market Share by Primary Input Data in 2025

Figure 17. Sequence and Genome Annotation Data

Figure 18. Sanger Sequencing Data

Figure 19. Targeted Amplicon NGS Data

Figure 20. Genome-Wide NGS Data

Figure 21. Long-Read Sequencing Data

Figure 22. Multi-Assay Data

Figure 23. Global Gene Editing Safety Analysis Software Consumption Value by Application, (USD Million), 2021 & 2025 & 2032

Figure 24. Gene Editing Safety Analysis Software Consumption Value Market Share by Application in 2025

Figure 25. Biopharmaceutical and Cell & Gene Therapy Companies Picture

Figure 26. Clinical and Independent Testing Laboratories Picture

Figure 27. Academic and Government Research Institutes Picture

- Figure 28. Agricultural Biotechnology Companies Picture
- Figure 29. Industrial Biotechnology Companies Picture
- Figure 30. Global Gene Editing Safety Analysis Software Consumption Value, (USD Million): 2021 & 2025 & 2032
- Figure 31. Global Gene Editing Safety Analysis Software Consumption Value and Forecast (2021-2032) & (USD Million)
- Figure 32. Global Market Gene Editing Safety Analysis Software Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
- Figure 33. Global Gene Editing Safety Analysis Software Consumption Value Market Share by Region (2021-2032)
- Figure 34. Global Gene Editing Safety Analysis Software Consumption Value Market Share by Region in 2025
- Figure 35. North America Gene Editing Safety Analysis Software Consumption Value (2021-2032) & (USD Million)
- Figure 36. Europe Gene Editing Safety Analysis Software Consumption Value (2021-2032) & (USD Million)
- Figure 37. Asia-Pacific Gene Editing Safety Analysis Software Consumption Value (2021-2032) & (USD Million)
- Figure 38. South America Gene Editing Safety Analysis Software Consumption Value (2021-2032) & (USD Million)
- Figure 39. Middle East & Africa Gene Editing Safety Analysis Software Consumption Value (2021-2032) & (USD Million)
- Figure 40. Company Three Recent Developments and Future Plans
- Figure 41. Global Gene Editing Safety Analysis Software Revenue Share by Players in 2025
- Figure 42. Gene Editing Safety Analysis Software Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
- Figure 43. Market Share of Gene Editing Safety Analysis Software by Player Revenue in 2025
- Figure 44. Top 3 Gene Editing Safety Analysis Software Players Market Share in 2025
- Figure 45. Top 6 Gene Editing Safety Analysis Software Players Market Share in 2025
- Figure 46. Global Gene Editing Safety Analysis Software Consumption Value Share by Type (2021-2026)
- Figure 47. Global Gene Editing Safety Analysis Software Market Share Forecast by Type (2027-2032)
- Figure 48. Global Gene Editing Safety Analysis Software Consumption Value Share by Application (2021-2026)
- Figure 49. Global Gene Editing Safety Analysis Software Market Share Forecast by Application (2027-2032)

Figure 50. North America Gene Editing Safety Analysis Software Consumption Value Market Share by Type (2021-2032)

Figure 51. North America Gene Editing Safety Analysis Software Consumption Value Market Share by Application (2021-2032)

Figure 52. North America Gene Editing Safety Analysis Software Consumption Value Market Share by Country (2021-2032)

Figure 53. United States Gene Editing Safety Analysis Software Consumption Value (2021-2032) & (USD Million)

Figure 54. Canada Gene Editing Safety Analysis Software Consumption Value (2021-2032) & (USD Million)

Figure 55. Mexico Gene Editing Safety Analysis Software Consumption Value (2021-2032) & (USD Million)

Figure 56. Europe Gene Editing Safety Analysis Software Consumption Value Market Share by Type (2021-2032)

Figure 57. Europe Gene Editing Safety Analysis Software Consumption Value Market Share by Application (2021-2032)

Figure 58. Europe Gene Editing Safety Analysis Software Consumption Value Market Share by Country (2021-2032)

Figure 59. Germany Gene Editing Safety Analysis Software Consumption Value (2021-2032) & (USD Million)

Figure 60. France Gene Editing Safety Analysis Software Consumption Value (2021-2032) & (USD Million)

Figure 61. United Kingdom Gene Editing Safety Analysis Software Consumption Value (2021-2032) & (USD Million)

Figure 62. Russia Gene Editing Safety Analysis Software Consumption Value (2021-2032) & (USD Million)

Figure 63. Italy Gene Editing Safety Analysis Software Consumption Value (2021-2032) & (USD Million)

Figure 64. Asia-Pacific Gene Editing Safety Analysis Software Consumption Value Market Share by Type (2021-2032)

Figure 65. Asia-Pacific Gene Editing Safety Analysis Software Consumption Value Market Share by Application (2021-2032)

Figure 66. Asia-Pacific Gene Editing Safety Analysis Software Consumption Value Market Share by Region (2021-2032)

Figure 67. China Gene Editing Safety Analysis Software Consumption Value (2021-2032) & (USD Million)

Figure 68. Japan Gene Editing Safety Analysis Software Consumption Value (2021-2032) & (USD Million)

Figure 69. South Korea Gene Editing Safety Analysis Software Consumption Value

(2021-2032) & (USD Million)

Figure 70. India Gene Editing Safety Analysis Software Consumption Value

(2021-2032) & (USD Million)

Figure 71. Southeast Asia Gene Editing Safety Analysis Software Consumption Value

(2021-2032) & (USD Million)

Figure 72. Australia Gene Editing Safety Analysis Software Consumption Value

(2021-2032) & (USD Million)

Figure 73. South America Gene Editing Safety Analysis Software Consumption Value

Market Share by Type (2021-2032)

Figure 74. South America Gene Editing Safety Analysis Software Consumption Value

Market Share by Application (2021-2032)

Figure 75. South America Gene Editing Safety Analysis Software Consumption Value

Market Share by Country (2021-2032)

Figure 76. Brazil Gene Editing Safety Analysis Software Consumption Value

(2021-2032) & (USD Million)

Figure 77. Argentina Gene Editing Safety Analysis Software Consumption Value

(2021-2032) & (USD Million)

Figure 78. Middle East & Africa Gene Editing Safety Analysis Software Consumption

Value Market Share by Type (2021-2032)

Figure 79. Middle East & Africa Gene Editing Safety Analysis Software Consumption

Value Market Share by Application (2021-2032)

Figure 80. Middle East & Africa Gene Editing Safety Analysis Software Consumption

Value Market Share by Country (2021-2032)

Figure 81. Turkey Gene Editing Safety Analysis Software Consumption Value

(2021-2032) & (USD Million)

Figure 82. Saudi Arabia Gene Editing Safety Analysis Software Consumption Value

(2021-2032) & (USD Million)

Figure 83. UAE Gene Editing Safety Analysis Software Consumption Value (2021-2032)

& (USD Million)

Figure 84. Gene Editing Safety Analysis Software Market Drivers

Figure 85. Gene Editing Safety Analysis Software Market Restraints

Figure 86. Gene Editing Safety Analysis Software Market Trends

Figure 87. Porters Five Forces Analysis

Figure 88. Gene Editing Safety Analysis Software Industrial Chain

Figure 89. Methodology

Figure 90. Research Process and Data Source

## I would like to order

Product name: Global Gene Editing Safety Analysis Software Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Product link: <https://marketpublishers.com/r/GD9A022933B6EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GD9A022933B6EN.html>